We have developed a reduced-intensity conditioning regimen for patients with severe aplastic anemia (SAA) undergoing alternative donor transplants, which includes. udarabine (120 mg/m(2)), cyclophosphamide (1200 mg/m(2)) and antithymocyte globulin (7.5 mg/ kg). Graft-versus-host disease (GvHD) prophylaxis consisted of cyclosporine and methotrexate. We have enrolled 38 SAA patients in this trial: median age of 14 (3-37) years, transplanted from unrelated (n=33) or family mismatched (n=5) donors, with unmanipulated marrow (n=36) or peripheral blood (n=2). Seven patients (18%) had evidence of graft failure, 11% developed grade II-III acute GvHD and 27% developed chronic GvHD. The actuarial 2-year survival is 73%, with a median follow-up of 621 days. Younger patients (<= 14 years) had a lower risk of rejection (5%) and improved actuarial survival (84%). Causes of death were infections (n=3), graft failure (n=2), Epstein-Barr virus lymphoma (n=2) and hemorrhage (n=2). In conclusion, the actuarial 2-year survival is encouraging in young SAA patients receiving a radiation-free conditioning regimen. The significant risk of graft failure in patients 15 years or older may require modification of the conditioning regimen in adults.

Bacigalupo, A., Locatelli, F., Lanino, E., Marsh, J., Socié, G., Maury, S., Prete, A., Locasciulli, A., Cesaro, S., Passweg, J., Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party, <<BONE MARROW TRANSPLANTATION>>, 2005; 36 (147): 947-950. [doi:10.1038/sj.bmt.1705165] [https://hdl.handle.net/10807/259137]

Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party

Bacigalupo, Andrea;Locatelli, Franco;
2005

Abstract

We have developed a reduced-intensity conditioning regimen for patients with severe aplastic anemia (SAA) undergoing alternative donor transplants, which includes. udarabine (120 mg/m(2)), cyclophosphamide (1200 mg/m(2)) and antithymocyte globulin (7.5 mg/ kg). Graft-versus-host disease (GvHD) prophylaxis consisted of cyclosporine and methotrexate. We have enrolled 38 SAA patients in this trial: median age of 14 (3-37) years, transplanted from unrelated (n=33) or family mismatched (n=5) donors, with unmanipulated marrow (n=36) or peripheral blood (n=2). Seven patients (18%) had evidence of graft failure, 11% developed grade II-III acute GvHD and 27% developed chronic GvHD. The actuarial 2-year survival is 73%, with a median follow-up of 621 days. Younger patients (<= 14 years) had a lower risk of rejection (5%) and improved actuarial survival (84%). Causes of death were infections (n=3), graft failure (n=2), Epstein-Barr virus lymphoma (n=2) and hemorrhage (n=2). In conclusion, the actuarial 2-year survival is encouraging in young SAA patients receiving a radiation-free conditioning regimen. The significant risk of graft failure in patients 15 years or older may require modification of the conditioning regimen in adults.
2005
Inglese
Bacigalupo, A., Locatelli, F., Lanino, E., Marsh, J., Socié, G., Maury, S., Prete, A., Locasciulli, A., Cesaro, S., Passweg, J., Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party, <<BONE MARROW TRANSPLANTATION>>, 2005; 36 (147): 947-950. [doi:10.1038/sj.bmt.1705165] [https://hdl.handle.net/10807/259137]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/259137
Citazioni
  • ???jsp.display-item.citation.pmc??? 33
  • Scopus 158
  • ???jsp.display-item.citation.isi??? 142
social impact